Dr Reddy’s Must Notify Celgene Of Plans To Sell Revlimid Generic In Australia
Three-Month Notice Period Will Give Originator The Opportunity To Seek An Injunction
Executive Summary
Australia’s Federal Court has ordered Dr Reddy’s to provide Celgene with three months written notice that it intends to bring a generic lenalidomide Revlimid rival to market.
You may also be interested in...
Dr Reddy’s Eyes Generic Revlimid Exclusivity With ANDA Approval
With Natco poised to debut the first batch of Revlimid generics in the US in March next year, fellow Indian ANDA sponsor Dr Reddy’s Laboratories has secured its own approval from the FDA for two strengths of the blockbuster multiple myeloma treatment.
Revlimid Rivals Debut In Canada
Dr Reddy’s and Natco have announced launches of Canadian rivals to Celgene’s Revlimid, with lenalidomide capsules from both companies made available from the start of September following settlements with the originator.
Sun Settles On Revlimid As Natco Scoops First ANDA Approval
Sun Pharma has become the latest ANDA sponsor to settle litigation with Celgene over Revlimid, shortly after Natco and partner Teva picked up the first ANDA approval for the blockbuster treatment for multiple myeloma.